BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29045960)

  • 41. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tacrolimus - Pharmacokinetic Considerations for Clinicians.
    Schutte-Nutgen K; Tholking G; Suwelack B; Reuter S
    Curr Drug Metab; 2018; 19(4):342-350. PubMed ID: 29298646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Once-daily tacrolimus in living donor liver transplant recipients.
    Sugawara Y; Miyata Y; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Yamashiki N; Kokudo N
    Biosci Trends; 2011 Aug; 5(4):156-8. PubMed ID: 21914950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator.
    Ihara H; Shinkuma D; Ichikawa Y; Nojima M; Nagano S; Ikoma F
    Int J Urol; 1995 Jul; 2(3):151-5. PubMed ID: 8536129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
    Staatz CE; Willis C; Taylor PJ; Tett SE
    Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative pharmacokinetics of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
    Vondrak K; Dhawan A; Parisi F; Grenda R; Debray D; Marks SD; Webb NJA; Lachaux A; Kazeem G; Undre N
    Pediatr Transplant; 2018 Dec; 22(8):e13289. PubMed ID: 30358019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
    Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE
    Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
    Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
    Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.
    Zhao W; Maisin A; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 May; 69(5):1181-5. PubMed ID: 23208323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients.
    Min DI; Chen HY; Lee MK; Ashton K; Martin MF
    Pharmacotherapy; 1997; 17(3):457-63. PubMed ID: 9165550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients.
    David-Neto E; Agena F; Ramos F; Triboni AHK; Romano P; de Almeida Rezende Ebner P; Coelho V; Galante NZ; Lemos FBC
    Transplantation; 2017 Sep; 101(9):2133-2138. PubMed ID: 27798513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study.
    Tsunashima D; Kawamura A; Murakami M; Sawamoto T; Undre N; Brown M; Groenewoud A; Keirns JJ; Holman J; Connor A; Wylde H; Wilding I; Ogawara K; Sako K; Higaki K; First R
    Clin Ther; 2014 May; 36(5):748-59. PubMed ID: 24680768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.